Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats

Journal of Hepatology

Volumn 60, Issue 6, 2014, Pages 1135-1142

  Schwabl, Philipp ^a,b   Payer, Berit A ^a,b   Grahovac, Jelena ^c   Klein, Sabine ^d   Horvatits, Thomas ^a   Mitterhauser, Markus ^a   Stift, Judith ^a   Boucher, Yves ^c   Trebicka, Jonel ^d   Trauner, Michael ^a   Angermayr, Bernhard ^a,b   Fuhrmann, Valentin ^a   Reiberger, Thomas ^a,b,c   Peck Radosavljevic, Markus ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vienna Hepatic Hemodynamic Lab   (Austria)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Angiogenesis; BDL; Inflammation; Pioglitazone; Portal hypertension; Portosystemic shunting; PPAR ; PPVL

Indexed keywords

ANGIOPOIETIN 2; CD31 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CXCL2 CHEMOKINE; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 5; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; ALPHA SMOOTH MUSCLE ACTIN; DIMETHYL SULFOXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; BILE DUCT LIGATION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HEMODYNAMICS; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER WEIGHT; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERICYTE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANGIOGENESIS; BLOOD FLOW; BODY WEIGHT; CELL VIABILITY; CIRRHOTIC PORTAL HYPERTENSION; INFLAMMATION; LIVER; MESENTERY BLOOD VESSEL; NON CIRRHOTIC PORTAL HYPERTENSION; PHENOTYPE; POLYMERASE CHAIN REACTION; PORTAL VEIN BLOOD; PORTAL VEIN LIGATION; SMALL INTESTINE; SYSTEMIC CIRCULATION; VASODILATATION; VEIN LIGATION; WOUND CLOSURE; ANIMAL; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, PORTAL; IMMUNOLOGY; LIVER CIRCULATION; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PORTAL; HYPOGLYCEMIC AGENTS; INFLAMMATION; LIVER CIRCULATION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; PORTAL PRESSURE; PPAR GAMMA; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION; THIAZOLIDINEDIONES;

EID: 84901193207     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.01.025     Document Type: Article

References (39)

1. J. Bosch, and J.C. Garcia-Pagan Complications of cirrhosis I. Portal hypertension J Hepatol 32 2000 141 156
2. R.J. Groszmann, and J.G. Abraldes Portal hypertension: from bedside to bench Clin Gastroenterol 39 2005 S125 S130
3. T. Reiberger, B. Angermayr, P. Schwabl, N. Rohr-Udilova, M. Mitterhauser, and A. Gangl et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats J Hepatol 51 2009 865 873
4. G. Garcia-Tsao, and J. Bosch Management of varices and variceal hemorrhage in cirrhosis N Engl J Med 362 2010 823 832
5. G. Garcia-Tsao Portal hypertension Curr Opin Gastroenterol 22 2006 254 262
6. P. Gines, M. Guevara, V. Arroyo, and J. Rodes Hepatorenal syndrome Lancet 362 2003 1819 1827
7. J. Bosch Vascular deterioration in cirrhosis: the big picture J Clin Gastroenterol 41 2007 S247 S253
8. J. Trebicka, M. Hennenberg, W. Laleman, N. Shelest, E. Biecker, and M. Schepke et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of rhoa/Rho-kinase and activation of endothelial nitric oxide synthase Hepatology 46 2007 242 253
9. M. Fernandez, D. Semela, J. Bruix, I. Colle, M. Pinzani, and J. Bosch Angiogenesis in liver disease J Hepatol 50 2009 604 620
10. A. Rodriguez-Vilarrupla, M. Fernandez, J. Bosch, and J.C. Garcia-Pagan Current concepts on the pathophysiology of portal hypertension Ann Hepatol 6 2007 28 36
11. S. Tugues, G. Fernandez-Varo, J. Munoz-Luque, J. Ros, V. Arroyo, and J. Rodes et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats Hepatology 46 2007 1919 1926
12. T. Reiberger, B.A. Payer, P. Schwabl, H. Hayden, T. Horvatits, and B. Jager et al. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling Liver Int 33 2013 561 568
13. C. Van Steenkiste, A. Geerts, E. Vanheule, H. Van Vlierberghe, F. De Vos, and K. Olievier et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension Gastroenterology 137 2009 e2111 e2116
14. M. Fernandez, M. Mejias, E. Garcia-Pras, R. Mendez, J.C. Garcia-Pagan, and J. Bosch Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats Hepatology 46 2007 1208 1217
15. R. de Franchis Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
16. M. Peck-Radosavljevic, B. Angermayr, C. Datz, A. Ferlitsch, M. Ferlitsch, and V. Fuhrmann et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) Wien Klin Wochenschr 125 2013 200 219
17. T. Reiberger, G. Ulbrich, A. Ferlitsch, B.A. Payer, P. Schwabl, and M. Pinter et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol Gut 62 2013 1634 1641
18. S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group Diabetes care 23 2000 1605 1611
19. L. Moezi, R. Heidari, Z. Amirghofran, A.A. Nekooeian, A. Monabati, and A.R. Dehpour Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1beta Pharmacol Rep 65 2013 134 143
20. R.T. Mattos, A.A. Bosco, and J.A. Nogueira-Machado Rosiglitazone, a PPAR-gamma agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes Inflamm Res 61 2012 37 41
21. D. Panigrahy, S. Singer, L.Q. Shen, C.E. Butterfield, D.A. Freedman, and E.J. Chen et al. Ppargamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J Clin Invest 110 2002 923 932
22. S. Buss Zda, Y.S. Medeiros, and T.S. Frode PPAR-gamma agonist rosiglitazone attenuates the inflammation caused by carrageenan in the mouse model of pleurisy Inflammation 35 2012 280 288
23. X. Xin, S. Yang, J. Kowalski, and M.E. Gerritsen Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo J Biol Chem 274 1999 9116 9121
24. B. Angermayr, M. Fernandez, M. Mejias, J. Gracia-Sancho, J.C. Garcia-Pagan, and J. Bosch NAD (P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats Gut 56 2007 560 564
25. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, and N.M. Bass et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
26. Y. Nishimoto, T. Tomida, H. Matsui, T. Ito, and K. Okumura Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats Hypertension 40 2002 190 194
27. D. Gao, N. Ning, G. Hao, and X. Niu Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats PPAR Res 2012 2012 856426
28. M. Hennenberg, J. Trebicka, C. Stark, A.Z. Kohistani, J. Heller, and T. Sauerbruch Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis Br J Pharmacol 157 2009 258 270
29. S. Klein, M.M. Van Beuge, M. Granzow, L. Beljaars, R. Schierwagen, and S. Kilic et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects J Hepatol 57 2012 1220 1227
30. J. Trebicka, L. Leifeld, M. Hennenberg, E. Biecker, A. Eckhardt, and N. Fischer et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats Hepatology 47 2008 1264 1276
31. J. Grahovac, D. Becker, and A. Wells Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C J Invest Dermatol 133 2013 210 220
32. W. Sieghart, M. Pinter, B. Dauser, N. Rohr-Udilova, A.C. Piguet, and G. Prager et al. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma J Hepatol 57 2012 592 599
33. V. Ratziu, P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann-Heurtier, and L. Serfaty et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial Gastroenterology 135 2008 100 110
34. F. Zhang, D. Kong, L. Chen, X. Zhang, N. Lian, and X. Zhu et al. Peroxisome proliferator-activated receptor-gamma interrupts angiogenic signal transduction via transrepression of platelet-derived growth factor-beta receptor in hepatic stellate cells J Cell Sci 127 Pt 2 2014 305 314
35. M. Fernandez, M. Mejias, B. Angermayr, J.C. Garcia-Pagan, J. Rodes, and J. Bosch Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats J Hepatol 43 2005 98 103
36. C. Van Steenkiste, J. Ribera, A. Geerts, M. Pauta, S. Tugues, and C. Casteleyn et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice Hepatology 53 2011 1629 1640
37. M. Barbieri, C. Di Filippo, A. Esposito, R. Marfella, M.R. Rizzo, and M. D'Amico et al. Effects of ppars agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-gamma-knockout (CM-PGKO) mice PLoS One 7 2012 e35999
38. S. Hauser, G. Adelmant, P. Sarraf, H.M. Wright, E. Mueller, and B.M. Spiegelman Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation J Biol Chem 275 2000 18527 18533
39. K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, and T. Heller et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196